ESMO Congress | Conference

Dr. Patrick M. Forde on Neoadjuvant Nivolumab in NSCLC

October 20th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).

Novel HER2-Targeting Antibody-Drug Conjugate Shows Broad Antitumor Activity

October 20th 2016

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Long-Term Follow-Up Supports Frontline Dabrafenib/Trametinib in Melanoma

October 20th 2016

Co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Niraparib Expected to Change Practice in Ovarian Cancer

October 19th 2016

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

Streamlined BRCA Testing Program Shows Promise in Ovarian Cancer

October 19th 2016

An interim analysis of an ongoing study showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

October 19th 2016

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer

October 19th 2016

The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.

Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers

October 18th 2016

Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

October 18th 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

October 17th 2016

Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.

No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy

October 12th 2016

Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

October 11th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

October 11th 2016

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC

October 11th 2016

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study

October 11th 2016

First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.

Frontline Cabozantinib Bests Sunitinib in mRCC

October 11th 2016

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.

First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer

October 10th 2016

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.

Nivolumab Misses PFS Endpoint in First-Line Advanced NSCLC

October 10th 2016

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.